Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Pan-KRAS inhibitors have the potential to address broad patient populations, including KRASG12D -, KRASG12V -, KRASG13D -, KRASG12R -, and KRASG12A -mutant or KRAS wild-type amplified cancers, as well as cancers with acquired resistance to KRAS G12C inhibitors.
Hofmann et al. 2022 Cancer Discov 12: 924-37…